[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"article-CSN-090426101--":3,"related-articles-undefined-undefined-3b0c143a-1ddd-4edc-8eae-c9192ac88aac-true":15},{"id":4,"type":5,"title":6,"pubDate":7,"logoUrl":8,"anpFeedCategory":9,"organisationTitle":10,"thirdParty":11,"body":12,"orgId":13,"description":14},"CSN-090426101","PRESSRELEASE"," DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unre","2026-04-09T14:17:20.000+02:00","https:\u002F\u002Fwww.persberichten.nl\u002Fimg\u002Fpr-newswire.png","Economie","PR Newswire",true,"\u003Cp> SHANGHAI, April 9, 2026 \u002FPRNewswire\u002F -- DualityBio (\"DualityBio\" or the \"Company\", Stock Code: 9606.HK) today announced that the Biologics License Application (BLA) for the investigational antibody-drug conjugate (\"ADC\") trastuzumab pamirtecan (\"T-Pam\", also known as DB-1303 or BNT323), has been accepted for review by the China National Medical Products Administration (NMPA). With the BLA filing, DualityBio is seeking approval for trastuzumab pamirtecan as second-line treatment for patients with unresectable or metastatic HER2-positive breast cancer. The application is based on positive interim results from the pivotal Phase III clinical trial (Study DB-1303-O-3001).\u003C\u002Fp>\u003Cp> The DB-1303-O-3001 trial is a randomized, controlled, open-label, multicenter Phase III clinical trial conducted in China. It aims to evaluate the efficacy and safety of trastuzumab pamirtecan compared to trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or metastatic breast cancer who have previously received trastuzumab and taxane chemotherapy. As assessed by the Independent Data Monitoring Committee (IDMC), the trial has met its primary endpoint of statistically significant improvement of progression-free survival (PFS, assessed by Blinded Independent Central Review, BICR) for trastuzumab pamirtecan compared to T-DM1 at a pre-specified interim analysis.\u003C\u002Fp>\u003Cp> \"China has over 350,000 new breast cancer cases annually , representing a high incidence rate and ranking as the second most common cancer among Chinese women. We are delighted to see that DB-1303\u002FT-Pam has achieved a milestone in its commercialization progress, demonstrating its potential to provide an effective new treatment option for breast cancer patients. In the China market, we have entered into a collaboration with 3SBio to jointly advance the commercialization of multiple indications of DB-1303\u002FT-Pam in Chinese mainland, Hong Kong and Macao. Globally, we will continue to deepen our global strategic partnership with BioNTech to further drive the global development of this product. DB-1303\u002FT-Pam is a globally co-developed new drug with strong strategic partners in both China and global markets. We will work closely together to accelerate the product's marketing approval process, maximize its global clinical value, present more treatment options to patients worldwide.\"\u003C\u002Fp>\u003Cp> Trastuzumab pamirtecan (\"T-Pam\", also known as BNT323 or DB-1303) is a third-generation topoisomerase-1 inhibitor-based ADC targeting HER2 which is being developed by BioNTech and DualityBio. Trastuzumab pamirtecan was built from DualityBio's proprietary Duality Immune Toxin Antibody Conjugates (\"DITAC\") platform. HER2 is a surface-expressed protein on solid tumors and has been linked to the aggressive growth and spread of cancer cells, making it a potential target for innovative cancer therapeutics. The candidate has exhibited antitumor activity in both HER2-positive and HER2-low tumor models as well as in several solid tumor indications, including patients with breast and endometrial cancers, as well as other advanced solid tumors. Preclinical data and preliminary clinical data for trastuzumab pamirtecan indicate its potential to target HER2 receptors on solid tumors irrespective of expression level with a manageable safety profile and a potentially expanded therapeutic window. Trastuzumab pamirtecan is currently being evaluated in multiple solid tumor types and innovative treatment combinations, including two global pivotal clinical trials in first-line HER2-low, hormone receptor positive (\"HR+\") metastatic breast cancer (DYNASTY-Breast02; NCT06018337) and second-line endometrial cancer (BNT323-01; ), a novel-novel combination Phase 1\u002F2 clinical trial (BNT323-03; ) evaluating trastuzumab pamirtecan in combination with pumitamig in HR-positive or –negative, HER2-low, -ultra-low, or -null advanced\u002Fmetastatic breast cancer and a Phase III, randomized, multi-site, open-label trial of BNT323\u002FDB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer (NCT06340568) .\u003C\u002Fp>\u003Cp> The BNT323\u002FDB-1303 program received the Fast Track designation and Breakthrough Therapy designation from the U.S. Food and Drug Administration (\"FDA\") for the treatment of endometrial cancer in 2023.\u003C\u002Fp>\u003Cp> Duality Biotherapeutics (HKEX:09606) is a clinical-stage biotech company dedicated to the discovery and development of next-generation ADCs to treat cancer and autoimmune diseases. DualityBio has successfully built several cutting-edge ADC technology platforms with global intellectual property rights. Leveraging a robust pipeline, DualityBio is conducting multiple global clinical trials across 17 countries and has enrolled over 3,200 patients for multiple clinical-stage ADC candidates.\u003C\u002Fp>\u003Cp> Additionally, DualityBio has established strategic collaborations with global MNCs and leading biotech innovators. As a global ADC powerhouse, DualityBio is developing novel ADCs, including bispecific ADC candidates, novel-payload ADC candidates, and autoimmune ADC candidates.\u003C\u002Fp>\u003Cp> For more information, please visit\u003C\u002Fp>\u003Cp> View original content: https:\u002F\u002Fwww.prnewswire.co.uk\u002Fnews-releases\u002Fdualitybio-announces-china-nmpa-acceptance-of-biologics-license-application-seeking-approval-for-trastuzumab-pamirtecan-for-the-treatment-of-unresectable-or-metastatic-her2-positive-adult-breast-cancer-302738250.html\u003C\u002Fp>","3b0c143a-1ddd-4edc-8eae-c9192ac88aac","SHANGHAI, April 9, 2026 \u002FPRNewswire\u002F -- DualityBio (\"DualityBio\" or the \"Company\", Stock Code: 9606.HK) today announced that the Biologics License Application (",[16,21,26,31,36,41,46,51,56,61],{"id":17,"title":18,"pubDate":19,"logoUrl":8,"thirdParty":11,"orgId":13,"description":20},"CSN-201126178"," APEC CEO Summit 2026 Concludes Successfully in Shenzhen","2026-11-20T23:44:25.000+01:00","SHENZHEN, China, Nov. 20, 2026 \u002FPRNewswire\u002F -- The APEC CEO Summit 2026 concluded on November 18 at the Qianhai International Convention Center in Shenzhen. Hos",{"id":22,"title":23,"pubDate":24,"logoUrl":8,"thirdParty":11,"orgId":13,"description":25},"CSN-201126147"," Huawei presenteert mogelijkheden voor het opschalen van AI in de financiële sector tijdens Singapore FinTech Festival 2026","2026-11-20T18:45:25.000+01:00","Met een open hybride AI-infrastructuur en drie intelligente fabrieken helpt Huawei financiële instellingen wereldwijd onderscheidende concurrentievoordelen te o",{"id":27,"title":28,"pubDate":29,"logoUrl":8,"thirdParty":11,"orgId":13,"description":30},"CSN-201126139"," New Amsterdam Invest heeft de eerder aangekondigde overname gerealiseerd.","2026-11-20T17:46:25.000+01:00","AMSTERDAM, 20 november 2026 \u002FPRNewswire\u002F -- New Amsterdam Invest N.V., een op Euronext Amsterdam genoteerde onderneming in commercieel vastgoed, bevestigt de af",{"id":32,"title":33,"pubDate":34,"logoUrl":8,"thirdParty":11,"orgId":13,"description":35},"CSN-201126135"," Guangzhou Nansha: GBA's strategic pivot for Asia-Pacific trade","2026-11-20T17:34:24.000+01:00","GUANGZHOU, China, Nov. 20, 2026 \u002FPRNewswire\u002F -- This is a news report from South. The 33rd Asia-Pacific Economic Cooperation (APEC) Economic Leaders' Meeting in",{"id":37,"title":38,"pubDate":39,"logoUrl":8,"thirdParty":11,"orgId":13,"description":40},"CSN-201126134"," Education Cannot Wait announces US$52 million to keep 300,000 children learning in Lebanon, Myanmar and South Sudan","2026-11-20T17:31:25.000+01:00","About 10% of the money is set aside for the next shock, and most of the funding goes to local organisations who know these communities GENEVA, Nov. 20, 2026 \u002FPR",{"id":42,"title":43,"pubDate":44,"logoUrl":8,"thirdParty":11,"orgId":13,"description":45},"CSN-201126128"," SDMC's Third Consecutive Year at Google's TV Summit, Showcasing Home Physical AI","2026-11-20T17:04:25.000+01:00","BANGKOK, Nov. 20, 2026 \u002FPRNewswire\u002F -- At Google's 2026 TV Summit in Bangkok, SDMC (00901.HK) returned as an invited speaker for the third consecutive year, adv",{"id":47,"title":48,"pubDate":49,"logoUrl":8,"thirdParty":11,"orgId":13,"description":50},"CSN-201126121"," RingConn Unveils The One Ring, a Limited-Edition Gen 3 Smart Ring Inspired by The Lord of the Rings Film Trilogy","2026-11-20T16:31:24.000+01:00","A limited-edition smart ring brings the iconic trilogy into everyday life, inviting users to begin their own journey of self-discovery and health awareness with",{"id":52,"title":53,"pubDate":54,"logoUrl":8,"thirdParty":11,"orgId":13,"description":55},"CSN-201126113"," OBSBOT Introduces Tail 2 ADV and Tail Air 2: Expanding Creative Freedom for Professional Production Teams and Creators","2026-11-20T15:15:25.000+01:00","Built on OBSBOT's proprietary AI tracking and pioneering PTZR innovation, two new Tail series cameras bring its vision of Autonomous Imaging into distinct produ",{"id":57,"title":58,"pubDate":59,"logoUrl":8,"thirdParty":11,"orgId":13,"description":60},"CSN-201126093"," Sun Yat-sen University Marks 160 Years of Medical Education and Sets Out Its Next Priorities","2026-11-20T14:01:24.000+01:00","GUANGZHOU, China, Nov. 20, 2026 \u002FPRNewswire\u002F -- Sun Yat-sen University (SYSU) marked the 160th anniversary of its medical education at an anniversary forum in G",{"id":62,"title":63,"pubDate":59,"logoUrl":8,"thirdParty":11,"orgId":13,"description":64},"CSN-201126091"," YESOUL Launches T5 Treadmill Series for Longevity-Focused Fitness","Featuring personalized Zone 2 training, low-impact incline walking, and up to 30% incline, the new series brings a versatile approach to lifelong fitness. HONG "]